Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.
Latest Ratings for BHVN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Mizuho | Maintains | Buy | |
| Jan 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Nov 2021 | Mizuho | Maintains | Buy |
